Compagnie Lombard Odier SCmA Invests $206,000 in Natera, Inc. (NASDAQ:NTRA)

Compagnie Lombard Odier SCmA acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,300 shares of the medical research company’s stock, valued at approximately $206,000.

Other large investors also recently modified their holdings of the company. Chartwell Investment Partners LLC grew its position in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after buying an additional 11,362 shares during the period. Cerity Partners LLC grew its position in shares of Natera by 27.0% during the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after buying an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Natera during the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. acquired a new stake in shares of Natera during the 4th quarter worth approximately $573,000. Finally, First Turn Management LLC acquired a new stake in shares of Natera during the 3rd quarter worth approximately $19,760,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Up 1.6 %

Shares of Natera stock opened at $173.39 on Friday. Natera, Inc. has a 1 year low of $68.03 and a 1 year high of $183.00. The firm has a market cap of $22.89 billion, a PE ratio of -98.52 and a beta of 1.66. The stock has a fifty day moving average price of $167.75 and a 200-day moving average price of $142.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the firm posted ($0.95) EPS. The business’s revenue was up 63.9% compared to the same quarter last year. Equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Robert W. Baird increased their target price on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. Barclays initiated coverage on Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. Finally, Guggenheim increased their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $165.88.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 663 shares of Natera stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 305,454 shares of company stock valued at $51,290,625. 7.60% of the stock is owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.